SQZ Biotechnologies Company (SQZB)
OTCMKTS: SQZB · Delayed Price · USD
0.0482
0.00 (0.00%)
Apr 19, 2024, 4:00 PM EDT - Market closed

Company Description

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions.

Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.

Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers.

The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

SQZ Biotechnologies Company
SQZ Biotechnologies Company logo
Country MA
Founded 2013
IPO Date Oct 30, 2020
Industry Biotechnology
Sector Healthcare
Employees 53

Contact Details

Address:
200 Arsenal Yards Blvd., Ste. 210
Watertown, Massachusetts 02472
United States
Phone 617-898-8824

Stock Details

Ticker Symbol SQZB
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001604477
Employer ID 46-2431115
SIC Code 2836

Key Executives

Name Position
Dr. Howard Bernstein M.D., Ph.D. Interim Chief Executive Officer and Director
Lawrence J. Knopf Esq. General Counsel and Secretary
Dr. Marshelle Smith Warren M.D. Chief Medical Officer
Dr. Robert S. Langer Jr., Ph.D. Co-Founder and Member of Scientific Advisory Board
Richard V. Capasso CPA Chief Accounting Officer
David First Chief People Officer
Ipsita Roymoulik Ph.D. Senior Vice President of CMC and QUALITY

Latest SEC Filings

Date Type Title
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 23, 2024 DEFM14A Filing
Jan 12, 2024 PREM14A Filing
Jan 4, 2024 15-12G Securities registration termination
Dec 22, 2023 8-K Current Report
Dec 1, 2023 EFFECT Notice of Effectiveness
Nov 30, 2023 POS AM Post-Effective amendments for registration statement
Nov 30, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Nov 8, 2023 10-Q Quarterly Report